WST · XBRL financial data

West Pharmaceutical Services financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (WST's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	—	695	—	—	—	—	—	—	—	—	—	—
Revenue from contracts with customers	732*	695	702	747	749*	698	767	805	805*	845	872	875
Cost of goods and services sold	454*	465	472	482	475*	466	493	510	501*	549	543	527
Gross profit	278*	230	230	265	274*	232	274	294	304*	296	329	347
Research and development	18*	18	18	16	19*	16	19	17	22*	16	20	18
Selling, general and administrative	90*	87	83	84	85*	88	96	103	107*	100	118	113
Other operating income (expense)	(0)*	(0)	0	(1)	0*	(0)	(0)	(0)	(0)*	0	(1)	(0)
Operating income (loss)	161*	123	126	161	160*	107	154	168	157*	177	179	267
Interest expense	1*	2	2	1	(1)*	0	0	0	(0)*	2	3	4
Other income (expense)	(1)*	0	0	(1)	(0)*	(0)	(0)	(0)	(0)*	(0)	(0)	(0)
Income tax expense (benefit)	35*	16	22	32	37*	24	30	34	33*	45	32	58
Net income (loss)	137*	115	111	136	130*	90	132	140	132*	139	154	214
Earnings per share, basic USD per share	1.85*	1.57	1.52	1.87	1.79*	1.24	1.82	1.94	1.83*	1.93	2.17	3.04
Earnings per share, diluted USD per share	1.83*	1.55	1.51	1.85	1.77*	1.23	1.82	1.92	1.82*	1.92	2.15	3.02
Weighted average shares, basic millions of shares	74*	74	73	73	73*	73	72	72	72*	72	71	70
Weighted average shares, diluted millions of shares	75*	74	74	73	73*	73	73	73	73*	72	71	71

Fiscal quarters (WST's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	854	602	446	491	485	404	510	629	791	521	436	464
Accounts receivable	512	524	479	524	553	544	582	625	574	686	712	748
Inventory	435	430	419	401	377	389	421	438	444	453	447	465
Total current assets	1,936	1,693	1,483	1,551	1,538	1,458	1,681	1,823	1,978	1,827	1,808	1,817
Property and equipment, net	1,413	1,449	1,494	1,571	1,582	1,632	1,722	1,741	1,726	1,702	1,686	1,672
Right-of-use asset	99	97	110	108	105	103	104	98	117	110	105	98
Goodwill	109	108	107	109	106	108	111	111	110	109	109	109
Total assets	3,830	3,602	3,489	3,675	3,643	3,618	3,953	4,106	4,270	4,110	4,076	4,061
Accounts payable	242	240	212	224	239	228	239	256	254	252	253	249
Accrued liabilities	—	—	—	—	—	—	—	—	39	47	34	39
Current portion of long-term debt	134	133	133	0	0	0	0	0	0	0	0	0
Total current liabilities	672	648	634	517	550	527	605	635	655	674	641	644
Long-term debt	73	73	73	203	203	203	203	203	203	203	203	203
Lease liability, non-current	85	82	85	82	82	79	80	74	96	92	88	83
Total liabilities	949	922	913	923	961	935	1,024	1,054	1,094	1,119	1,086	1,093
Retained earnings	3,523	3,624	3,721	3,857	3,957	4,031	4,139	4,262	4,375	4,476	4,624	4,817
Total stockholders' equity	2,881	2,681	2,577	2,752	2,682	2,683	2,929	3,052	3,176	2,990	2,990	2,968
Total liabilities and equity	3,830	3,602	3,489	3,675	3,643	3,618	3,953	4,106	4,270	4,110	4,076	4,061
Common shares outstanding (cover page) millions of shares	73	73	73	72	72	72	72	72	72	71	70	70

Fiscal quarters (WST's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	137*	115	111	136	130*	90	132	140	132*	139	154	214
Stock-based compensation	1*	5	4*	5*	4*	1	7*	8*	7*	7	11*	4*
Depreciation and amortization	year only	36	39	40	41*	40	41	43	47*	45	46	46
Net cash from operating activities	239*	118	165*	180*	190*	129	177*	197*	251*	90	124*	190*
Purchases of property and equipment	109*	91	100*	81*	105*	71	75*	63*	76*	43	43*	39*
Net cash from investing activities	(109)*	(91)	(101)*	(82)*	(105)*	(71)	(75)*	(63)*	(76)*	(43)	(43)*	79*
Share repurchases	177*	267	187*	52*	54*	134	1*	0*	0*	298	157*	231*
Dividends paid	15*	15	15*	15*	15*	15	15*	15*	16*	16	16*	16*
Proceeds from long-term debt	—	—	—	130*	—	—	—	—	—	—	—	—
Repayments of long-term debt	year only	1	36*	133*	0*	0	0*	0*	0*	—	—	—
Net cash from financing activities	(190)*	(271)	(218)*	(64)*	(69)*	(147)	(15)*	(12)*	(12)*	(309)	(165)*	(242)*
Net change in cash	(45)*	(252)	(156)*	45*	(6)*	(80)	106*	119*	163*	(270)	(86)*	28*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
West Pharmaceutical Services	464	875	190*	69.7M	—	Q3 FY26 10-QSep 30, 2026
Baxter International	1,975	2,976	558*	517.3M	—	Q3 FY26 10-QSep 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026
Hologic	2,168	1,048	230	223.2M	—	Q1 FY26 10-QDec 27, 2025
Solventum	403	2,209	227*	170.2M	—	Q2 FY26 10-QJun 30, 2026
Medline	2,327	7,685	715*	not reported	—	Q2 FY26 10-QJun 27, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
Align Technology	1,103	1,056	193*	71.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.